pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ROCHE · news · pharmadog
← back to ROCHE
News mentioning ROCHE
102
stories
11h
Roche pours $750M into Oregon manufacturing plant as obesity push expands
biospace
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
2d
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
7d
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
9d
Vaderis hauls in $152M to test an AKT-targeting drug
biopharma dive
9d
IRBs have a problem. Can North Star’s nonprofit model save it?
stat
10d
Labcorp nabs FDA green light for BRAF melanoma diagnostic
fiercebiotech
10d
FDA issues alert in wake of BD recall of faulty needle sets
fiercebiotech
13d
Why Big Pharma is chasing the industry’s most-powerful supercomputer
biopharma dive
14d
Roche adds cyclospora PCR tests as outbreak widens
fiercebiotech
15d
Attovia adds to biotech IPO momentum with $289M offering
biopharma dive
16d
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
17d
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
20d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
22d
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
22d
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
22d
Caldera, Vidya add to recent flurry of biotech mergers
biopharma dive
22d
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
biopharma dive
22d
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
biopharma dive
23d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
23d
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
biospace
23d
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
fiercebiotech
24d
RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC
fiercebiotech
24d
STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease
stat
25d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
27d
Roche cans one Carmot obesity asset as another shows best-in-class potential
biospace
28d
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
fiercebiotech
28d
FDA panel confronting peptide controversy
stat
28d
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
28d
Roche says it is thoughtful on token use for AI, shelves a drug from Carmot buy
endpoints
← prev
page 1 of 4
next →
